Brady Martz Wealth Solutions LLC Invests $502,000 in Thermo Fisher Scientific Inc. (NYSE:TMO)

Brady Martz Wealth Solutions LLC bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 901 shares of the medical research company's stock, valued at approximately $502,000.

Several other institutional investors have also recently modified their holdings of the company. International Assets Investment Management LLC increased its holdings in shares of Thermo Fisher Scientific by 76,051.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,416,416 shares of the medical research company's stock valued at $876,152,000 after purchasing an additional 1,414,556 shares in the last quarter. FMR LLC boosted its holdings in Thermo Fisher Scientific by 19.7% in the 3rd quarter. FMR LLC now owns 7,877,459 shares of the medical research company's stock worth $4,872,761,000 after buying an additional 1,294,453 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Thermo Fisher Scientific by 32.2% during the second quarter. Ameriprise Financial Inc. now owns 2,481,257 shares of the medical research company's stock worth $1,372,157,000 after buying an additional 604,895 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in Thermo Fisher Scientific in the 3rd quarter valued at about $254,412,000. Finally, Point72 Asset Management L.P. lifted its position in Thermo Fisher Scientific by 743.6% during the second quarter. Point72 Asset Management L.P. now owns 336,537 shares of the medical research company's stock worth $186,105,000 after buying an additional 296,646 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. StockNews.com raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. Barclays dropped their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a report on Wednesday, October 23rd. Royal Bank of Canada dropped their price objective on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. Sanford C. Bernstein raised Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 target price on the stock in a research note on Friday, January 10th. Finally, Redburn Atlantic started coverage on Thermo Fisher Scientific in a research report on Monday, October 14th. They issued a "buy" rating and a $680.00 target price for the company. Four research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $648.95.

Insider Activity at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the transaction, the senior vice president now owns 12,736 shares in the company, valued at $7,134,197.76. This trade represents a 13.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares in the company, valued at approximately $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,150 shares of company stock worth $25,954,465 in the last quarter. Company insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Stock Down 0.4 %

TMO stock traded down $1.99 during midday trading on Monday, reaching $559.72. 2,134,669 shares of the company were exchanged, compared to its average volume of 1,426,114. The stock's 50-day simple moving average is $529.96 and its 200 day simple moving average is $568.56. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The company has a market cap of $214.09 billion, a price-to-earnings ratio of 35.09, a price-to-earnings-growth ratio of 3.59 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to analysts' expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business's revenue was up .2% on a year-over-year basis. During the same period in the prior year, the firm earned $5.69 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were paid a dividend of $0.39 per share. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.78%.

Thermo Fisher Scientific announced that its board has approved a share repurchase program on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's leadership believes its stock is undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.